Evidence Snapshot: Pain

Enabling More Meaningful Evidence in Pain Studies

Pain trials fail at a striking rate. Fewer than 1% of new pain therapies advance from Phase I to FDA approval, versus roughly 6.5% across novel drugs overall. Why? Because trials still depend on infrequent, clinic-based scales that miss between-visit fluctuation and real-world function. Moreover, adding sample size has not fixed the problem.

This Evidence Snapshot makes the case for a different approach to pain measurement: frequent, at-home capture that pairs PROs with objective signals of activity, mobility, and physiology.

Inside the Pain Measurement Snapshot

• Why legacy pain scales like BPI, NRS-11, and VAS provide limited insight between clinic visits
• Two case studies in brief: recovery trajectories after hip replacement, and sickle cell pain episodes interpreted against individual baseline
• What context-driven pain measurement means for competitive advantage in pain programs

Download the snapshot, or contact Koneksa to discuss how this approach could be configured for your study.